Femasys (FEMY) vs Nephros (NEPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nephros (NEPH) has outperformed Femasys (FEMY) over the past year, losing 36.2% versus a loss of 82.9%. Over five years, NEPH leads with a -57.6% price change compared with -98.5% for FEMY. Nephros is the larger company by market cap ($35.7 million vs $17.1 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FEMY | NEPH |
|---|---|---|
| Share price | $2.05 | $3.29 |
| Market cap | $17.13M | $35.73M |
| 1-day change | +2.25% | +2.81% |
| YTD return | -82.25% | -32.58% |
| 1-year return | -82.87% | -36.24% |
| 5-year return | -98.54% | -57.60% |
| P/E ratio (TTM) | — | 21.93 |
| Forward P/E | — | 15.67 |
| EPS (TTM) | $-3.28 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.20 | $6.42 |
| 52-week low | $1.94 | $2.66 |
| Distance from 52-week high | -90.79% | -48.75% |
| Analyst consensus | none | none |
| Avg. price target upside | +600.73% | +89.97% |
| Average volume | 722.09K | 27.59K |
| Shares outstanding | 8.38M | 10.86M |
| Employees | 51 | 36 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nephros is about 2.1 times larger than Femasys by market value ($35.73M vs $17.13M).
- NEPH has outperformed FEMY by 46.6 percentage points over the past year.
About Femasys
FEMY stock →Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
Healthcare · Medical Instruments & Supplies · 51 employees
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Healthcare · Medical Instruments & Supplies · 36 employees
FEMY vs NEPH FAQ
Which is bigger, Femasys or Nephros?
Nephros (NEPH) is larger, with a market capitalization of $35.73M compared with $17.13M for Femasys (FEMY).
Which stock has performed better over the past year, FEMY or NEPH?
NEPH returned -36.24% over the past 12 months, compared with -82.87% for FEMY (price return, excluding dividends). Past performance does not predict future results.
Are Femasys and Nephros in the same industry?
Yes. Both are classified in the Medical Instruments & Supplies industry within the Healthcare sector.